Progress in Cardiovascular Diseases
Volume 51, Issue 1 , Pages 58-73 , July 2008

Sudden Cardiac Death in Infiltrative Cardiomyopathies: Sarcoidosis, Scleroderma, Amyloidosis, Hemachromatosis

References 

  1. Judson MA, Baughman RP, Teirstein AS, et al. Defining organ involvement in sarcoidosis: the ACCESS proposed instrument. ACCESS Research Group. A Case Control Etiologic Study of Sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 1999;16:75–86
  2. Rybicki BA, Hirst K, Iyengar SK, et al. A sarcoidosis genetic linkage consortium: the sarcoidosis genetic analysis (SAGA) study. Sarcoidosis Vasc Diffuse Lung Dis. 2005;22:115–122
  3. Bernstein M, Konzlemann FW, Sidlick DM. Boeck's sarcoid: report of a case with visceral involvement. Arch Intern Med. 1929;44:721–734
  4. Roberts WC, McAllister HA, Ferrans VJ. Sarcoidosis of the heart. A clinicopathologic study of 35 necropsy patients (group 1) and review of 78 previously described necropsy patients (group 11). Am J Med. 1977;63:86–108
  5. Mitchell DN, du Bois RM, Oldershaw PJ. Cardiac sarcoidosis. BMJ. 1997;314:320–321
  6. Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol. 2006;48:e247–e346
  7. Rybicki BA, Iannuzzi MC. Epidemiology of sarcoidosis: recent advances and future prospects. Semin Respir Crit Care Med. 2007;28:22–35
  8. Rossman MD, Thompson B, Frederick M, et al. HLA-DRB1*1101: a significant risk factor for sarcoidosis in blacks and whites. Am J Hum Genet. 2003;73:720–735
  9. Rybicki BA, Iannuzzi MC, Frederick MM, et al. Familial aggregation of sarcoidosis. A case-control etiologic study of sarcoidosis (ACCESS). Am J Respir Crit Care Med. 2001;164:2085–2091
  10. Baughman RP, Teirstein AS, Judson MA, et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med. 2001;164:1885–1889
  11. Silverman KJ, Hutchins GM, Bulkley BH. Cardiac sarcoid: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis. Circulation. 1978;58:1204–1211
  12. Sekiguchi M, Numao Y, Imai M. Clinical and histopathological profile of sarcoidosis of the heart and acute idiopathic myocarditis. Concepts through a study employing endomyocardial biopsy. I. Sarcoidosis. Jpn Circ J. 1980;44:249–263
  13. Matsui Y, Iwai K, Tachibana T, et al. Clinicopathological study of fatal myocardial sarcoidosis. Ann N Y Acad Sci. 1976;278:455–469
  14. Fleming HA. Sarcoid heart disease: a review and an appeal. Thorax. 1980;35:641–643
  15. Fleming HA, Bailey SM. The prognosis of sarcoid heart disease in the United Kingdom. Ann N Y Acad Sci. 1986;465:543–550
  16. Valantine H, McKenna WJ, Nihoyannopoulos P, et al. Sarcoidosis: a pattern of clinical and morphological presentation. Br Heart J. 1987;57:256–263
  17. Yager JE, Hernandez AF, Steenbergen C, et al. Recurrence of cardiac sarcoidosis in a heart transplant recipient. J Heart Lung Transplant. 2005;24:1988–1990
  18. Yazaki Y, Isobe M, Hiroe M, et al. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol. 2001;88:1006–1010
  19. Koplan BA, Soejima K, Baughman K, et al. Refractory ventricular tachycardia secondary to cardiac sarcoid: electrophysiologic characteristics, mapping, and ablation. Heart Rhythm. 2006;3:924–929
  20. Ott P, Marcus FI, Sobonya RE, et al. Cardiac sarcoidosis masquerading as right ventricular dysplasia. Pacing Clin Electrophysiol. 2003;26:1498–1503
  21. Furushima H, Chinushi M, Sugiura H, et al. Ventricular tachyarrhythmia associated with cardiac sarcoidosis: its mechanisms and outcome. Clin Cardiol. 2004;27:217–222
  22. Siltzbach LE. The Kveim test in sarcoidosis. A study of 750 patients. JAMA. 1961;178:476–482
  23. Ardehali H, Howard DL, Hariri A, et al. A positive endomyocardial biopsy result for sarcoid is associated with poor prognosis in patients with initially unexplained cardiomyopathy. Am Heart J. 2005;150:459–463
  24. Doughan AR, Williams BR. Cardiac sarcoidosis. Heart. 2006;92:282–288
  25. Stein E, Jackler I, Stimmel B, et al. Asymptomatic electrocardiographic alterations in sarcoidosis. Am Heart J. 1973;86:474–477
  26. Hiraga H, Yuwai K, Hiroe M, et al. Guidelines for the diagnosis of cardiac sarcoidosis: Study Report of Diffuse Pulmonary Diseases. Jpn Minist Health Welf. 1993;23–24
  27. Ishimaru S, Tsujino I, Takei T, et al. Focal uptake on 18F-fluoro-2-deoxyglucose positron emission tomography images indicates cardiac involvement of sarcoidosis. Eur Heart J. 2005;26:1538–1543
  28. Yamagishi H, Shirai N, Takagi M, et al. Identification of cardiac sarcoidosis with (13)N-NH(3)/(18)F-FDG PET. J Nucl Med. 2003;44:1030–1036
  29. Smedema JP, Snoep G, van Kroonenburgh MP, et al. Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol. 2005;45:1683–1690
  30. Vignaux O, Dhote R, Duboc D, et al. Clinical significance of myocardial magnetic resonance abnormalities in patients with sarcoidosis: a 1-year follow-up study. Chest. 2002;122:1895–1901
  31. Smedema JP, Snoep G, van Kroonenburgh MP, et al. Cardiac involvement in patients with pulmonary sarcoidosis assessed at two university medical centers in the Netherlands. Chest. 2005;128:30–35
  32. Aizer A, Stern EH, Gomes JA, et al. Usefulness of programmed ventricular stimulation in predicting future arrhythmic events in patients with cardiac sarcoidosis. Am J Cardiol. 2005;96:276–282
  33. Yasutake H, Seino Y, Kashiwagi M, et al. Detection of cardiac sarcoidosis using cardiac markers and myocardial integrated backscatter. Int J Cardiol. 2005;102:259–268
  34. Uslu N, Akyol A, Gorgulu S, et al. Heart rate variability in patients with systemic sarcoidosis. Ann Noninvasive Electrocardiol. 2006;11:38–42
  35. Uyarel H, Uslu N, Okmen E, et al. QT dispersion in sarcoidosis. Chest. 2005;128:2619–2625
  36. Yodogawa K, Seino Y, Ohara T, et al. Non-invasive detection of latent cardiac conduction abnormalities in patients with pulmonary sarcoidosis. Circ J. 2007;71:540–545
  37. Winters SL, Cohen M, Greenberg S, et al. Sustained ventricular tachycardia associated with sarcoidosis: assessment of the underlying cardiac anatomy and the prospective utility of programmed ventricular stimulation, drug therapy and an implantable antitachycardia device. J Am Coll Cardiol. 1991;18:937–943
  38. Kato Y, Morimoto S, Uemura A, et al. Efficacy of corticosteroids in sarcoidosis presenting with atrioventricular block. Sarcoidosis Vasc Diffuse Lung Dis. 2003;20:133–137
  39. Gregoratos G, Abrams J, Epstein AE, et al. ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines). J Cardiovasc Electrophysiol. 2002;13:1183–1199
  40. Takada K, Ina Y, Yamamoto M, et al. Prognosis after pacemaker implantation in cardiac sarcoidosis in Japan. Clinical evaluation of corticosteroid therapy. Sarcoidosis. 1994;11:113–117
  41. Zaidi AR, Zaidi A, Vaitkus PT. Outcome of heart transplantation in patients with sarcoid cardiomyopathy. J Heart Lung Transplant. 2007;26:714–717
  42. Gilliland BC. Systemic sclerosis (Scleroderma) and related disorders. In:  Kasper DL,  Braunwald E,  Fauci AS,  Hauser SL,  Longo DL,  Jameson JL editor. Harrison's principles of internal medicine. 16th ed.. New York: McGraw-Hill; 2005;p. 1979–1990
  43. Fonseca C, Lindahl GE, Ponticos M, et al. A polymorphism in the CTGF promoter region associated with systemic sclerosis. N Engl J Med. 2007;357:1210–1220
  44. Lawrence RC, Helmick CG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum. 1998;41:778–799
  45. Lee P, Langevitz P, Alderdice CA, et al. Mortality in systemic sclerosis (scleroderma). Q J Med. 1992;82:139–148
  46. D'Angelo WA, Fries JF, Masi AT, et al. Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med. 1969;46:428–440
  47. Byers RJ, Marshall DA, Freemont AJ. Pericardial involvement in systemic sclerosis. Ann Rheum Dis. 1997;56:393–394
  48. Ridolfi RL, Bulkley BH, Hutchins GM. The cardiac conduction system in progressive systemic sclerosis. Clinical and pathologic features of 35 patients. Am J Med. 1976;61:361–366
  49. Bulkley BH, Ridolfi RL, Salyer WR, et al. Myocardial lesions of progressive systemic sclerosis. A cause of cardiac dysfunction. Circulation. 1976;53:483–490
  50. Sackner MA, Heinz ER, Steinberg AJ. The heart in scleroderma. Am J Cardiol. 1966;17:542–559
  51. Roberts NK, Cabeen WR. Atrioventricular nodal function in progressive systemic sclerosis: electrophysiological and morphological findings. Br Heart J. 1980;44:529–533
  52. Janosik DL, Osborn TG, Moore TL, et al. Heart disease in systemic sclerosis. Semin Arthritis Rheum. 1989;19:191–200
  53. Bulkley BH, Klacsmann PG, Hutchins GM. Angina pectoris, myocardial infarction and sudden cardiac death with normal coronary arteries: a clinicopathologic study of 9 patients with progressive systemic sclerosis. Am Heart J. 1978;95:563–569
  54. Windesheim JH, Parkin TW. Electrocardiograms of ninety patients with acrosclerosis and progressive diffuse sclerosis (scleroderma). Circulation. 1958;17:874–881
  55. Follansbee WP, Curtiss EI, Rahko PS, et al. The electrocardiogram in systemic sclerosis (scleroderma). Study of 102 consecutive cases with functional correlations and review of the literature. Am J Med. 1985;79:183–192
  56. Kostis JB, Seibold JR, Turkevich D, et al. Prognostic importance of cardiac arrhythmias in systemic sclerosis. Am J Med. 1988;84:1007–1015
  57. Clements PJ, Furst DE, Cabeen W, et al. The relationship arrhythmias and conduction disturbances to other manifestations of cardiopulmonary disease in progressive systemic sclerosis (PSS). Am J Med. 1981;71:38–46
  58. Oram S, Stokes W. The heart in scleroderma. Br Heart J. 1961;23:243–259
  59. Paradiso M, Gabrielli F, Coppotelli L, et al. Signal-averaged electrocardiography and echocardiography in the evaluation of myocardial involvement in progressive systemic sclerosis. Int J Cardiol. 1996;53:171–177
  60. Morelli S, Sgreccia A, De Marzio P, et al. Noninvasive assessment of myocardial involvement in patients with systemic sclerosis: role of signal averaged electrocardiography. J Rheumatol. 1997;24:2358–2363
  61. Paradiso M, Di Franco M, Musca A, et al. Ventricular late potentials in systemic sclerosis: relationship with skin involvement. J Rheumatol. 2002;29:1388–1392
  62. Pancera P, Sansone S, Presciuttini B, et al. Autonomic nervous system dysfunction in sclerodermic and primary Raynaud's phenomenon. Clin Sci (Lond). 1999;96:49–57
  63. Di Franco M, Paradiso M, Riccieri V, et al. Autonomic dysfunction and microvascular damage in systemic sclerosis. Clin Rheumatol. 2007;26:1278–1283
  64. Morelli S, Piccirillo G, Fimognari F, et al. Twenty-four hour heart period variability in systemic sclerosis. J Rheumatol. 1996;23:643–645
  65. Sgreccia A, Morelli S, Ferrante L, et al. QT interval and QT dispersion in systemic sclerosis (scleroderma). J Intern Med. 1998;243:127–132
  66. Gaal J, Hegedus I, Devenyi K, et al. Myocardial gallium-67 citrate scintigraphy in patients with systemic sclerosis. Ann Rheum Dis. 1995;54:856–858
  67. Plastiras SC, Kelekis N, Tzelepis GE. Magnetic resonance imaging for the detection of myocardial fibrosis in scleroderma. N Engl J Med. 2006;354:2194–2196
  68. Ferri C, Giuggioli D, Sebastiani M, et al. Heart involvement and systemic sclerosis. Lupus. 2005;14:702–707
  69. Ferri C, Emdin M, Nielsen H, et al. Assessment of heart involvement. Clin Exp Rheumatol. 2003;21:S24–S28
  70. Bennett R, Bluestone R, Holt PJ, et al. Survival in scleroderma. Ann Rheum Dis. 1971;30:581–588
  71. Ferri C, Bernini L, Bongiorni MG, et al. Noninvasive evaluation of cardiac dysrhythmias, and their relationship with multisystemic symptoms, in progressive systemic sclerosis patients. Arthritis Rheum. 1985;28:1259–1266
  72. Rokas S, Mavrikakis M, Agrios N, et al. Electrophysiologic abnormalities of cardiac function in progressive systemic sclerosis. J Electrocardiol. 1996;29:17–25
  73. Paulisinski R, Chibowska M, Bilan A, et al. Enalapril (10 mg/day) in systemic sclerosis. One year, double blind, randomised study (ESS-1): electrocardiographic substudy—three months follow-up. Adv Exp Med Biol. 1999;455:295–298
  74. Lacroix D, Brigadeau F, Marquie C, et al. Electroanatomic mapping and ablation of ventricular tachycardia associated with systemic sclerosis. Europace. 2004;6:336–342
  75. Martinez-Taboada V, Olalla J, Blanco R, et al. Malignant ventricular arrhythmia in systemic sclerosis controlled with an implantable cardioverter defibrillator. J Rheumatol. 1994;21:2166–2167
  76. Kyle RA, Linos A, Beard CM, et al. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood. 1992;79:1817–1822
  77. Shah KB, Inoue Y, Mehra MR. Amyloidosis and the heart: a comprehensive review. Arch Intern Med. 2006;166:1805–1813
  78. Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation. 2005;112:2047–2060
  79. Connors LH, Richardson AM, Theberge R, et al. Tabulation of transthyretin (TTR) variants as of 1/1/2000. Amyloid. 2000;7:54–69
  80. Dubrey SW, Cha K, Simms RW, et al. Electrocardiography and Doppler echocardiography in secondary (AA) amyloidosis. Am J Cardiol. 1996;77:313–315
  81. Smith TJ, Kyle RA, Lie JT. Clinical significance of histopathologic patterns of cardiac amyloidosis. Mayo Clin Proc. 1984;59:547–555
  82. James TN. Pathology of the cardiac conduction system in amyloidosis. Ann Intern Med. 1966;65:28–36
  83. Mueller PS, Edwards WD, Gertz MA. Symptomatic ischemic heart disease resulting from obstructive intramural coronary amyloidosis. Am J Med. 2000;109:181–188
  84. Cantwell RV, Aviles RJ, Bjornsson J, et al. Cardiac amyloidosis presenting with elevations of cardiac troponin I and angina pectoris. Clin Cardiol. 2002;25:33–37
  85. Dispenzieri A, Kyle RA, Gertz MA, et al. Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet. 2003;361:1787–1789
  86. Chamarthi B, Dubrey SW, Cha K, et al. Features and prognosis of exertional syncope in light-chain associated AL cardiac amyloidosis. Am J Cardiol. 1997;80:1242–1245
  87. Murtagh B, Hammill SC, Gertz MA, et al. Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement. Am J Cardiol. 2005;95:535–537
  88. Dubrey SW, Cha K, Anderson J, et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM. 1998;91:141–157
  89. Siqueira-Filho AG, Cunha CL, Tajik AJ, et al. M-mode and two-dimensional echocardiographic features in cardiac amyloidosis. Circulation. 1981;63:188–196
  90. Cueto-Garcia L, Reeder GS, Kyle RA, et al. Echocardiographic findings in systemic amyloidosis: spectrum of cardiac involvement and relation to survival. J Am Coll Cardiol. 1985;6:737–743
  91. Klein AL, Hatle LK, Taliercio CP, et al. Serial Doppler echocardiographic follow-up of left ventricular diastolic function in cardiac amyloidosis. J Am Coll Cardiol. 1990;16:1135–1141
  92. Koyama J, Ray-Sequin PA, Falk RH. Longitudinal myocardial function assessed by tissue velocity, strain, and strain rate tissue Doppler echocardiography in patients with AL (primary) cardiac amyloidosis. Circulation. 2003;107:2446–2452
  93. Maceira AM, Joshi J, Prasad SK, et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2005;111:186–193
  94. Ardehali H, Qasim A, Cappola T, et al. Endomyocardial biopsy plays a role in diagnosing patients with unexplained cardiomyopathy. Am Heart J. 2004;147:919–923
  95. Falk RH, Rubinow A, Cohen AS. Cardiac arrhythmias in systemic amyloidosis: correlation with echocardiographic abnormalities. J Am Coll Cardiol. 1984;3:107–113
  96. Palladini G, Malamani G, Co F, et al. Holter monitoring in AL amyloidosis: prognostic implications. Pacing Clin Electrophysiol. 2001;24:1228–1233
  97. Dubrey SW, Bilazarian S, LaValley M, et al. Signal-averaged electrocardiography in patients with AL (primary) amyloidosis. Am Heart J. 1997;134:994–1001
  98. Reisinger J, Dubrey SW, Lavalley M, et al. Electrophysiologic abnormalities in AL (primary) amyloidosis with cardiac involvement. J Am Coll Cardiol. 1997;30:1046–1051
  99. Gertz MA, Falk RH, Skinner M, et al. Worsening of congestive heart failure in amyloid heart disease treated by calcium channel-blocking agents. Am J Cardiol. 1985;55:1645
  100. Rubinow A, Skinner M, Cohen AS. Digoxin sensitivity in amyloid cardiomyopathy. Circulation. 1981;63:1285–1288
  101. Skinner M, Sanchorawala V, Seldin DC, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med. 2004;140:85–93
  102. Feder JN, Gnirke A, Thomas W, et al. A novel MHC class I–like gene is mutated in patients with hereditary haemochromatosis. Nat Genet. 1996;13:399–408
  103. Girelli D, Bozzini C, Roetto A, et al. Clinical and pathologic findings in hemochromatosis type 3 due to a novel mutation in transferrin receptor 2 gene. Gastroenterology. 2002;122:1295–1302
  104. Lamon JM, Marynick SP, Roseblatt R, et al. Idiopathic hemochromatosis in a young female. A case study and review of the syndrome in young people. Gastroenterology. 1979;76:178–183
  105. Merryweather-Clarke AT, Pointon JJ, Shearman JD, et al. Global prevalence of putative haemochromatosis mutations. J Med Genet. 1997;34:275–278
  106. Pietrangelo A. Hereditary hemochromatosis—a new look at an old disease. N Engl J Med. 2004;350:2383–2397
  107. Rochette J, Pointon JJ, Fisher CA, et al. Multicentric origin of hemochromatosis gene (HFE) mutations. Am J Hum Genet. 1999;64:1056–1062
  108. Easley RM, Schreiner BF, Yu PN. Reversible cardiomyopathy associated with hemochromatosis. N Engl J Med. 1972;287:866–867
  109. Buja LM, Roberts WC. Iron in the heart. Etiology and clinical significance. Am J Med. 1971;51:209–221
  110. Vigorita VJ, Hutchins GM. Cardiac conduction system in hemochromatosis: clinical and pathologic features of six patients. Am J Cardiol. 1979;44:418–423
  111. Tuomainen TP, Kontula K, Nyyssonen K, et al. Increased risk of acute myocardial infarction in carriers of the hemochromatosis gene Cys282Tyr mutation : a prospective cohort study in men in eastern Finland. Circulation. 1999;100:1274–1279
  112. Ellervik C, Tybjaerg-Hansen A, Grande P, et al. Hereditary hemochromatosis and risk of ischemic heart disease: a prospective study and a case-control study. Circulation. 2005;112:185–193
  113. Palka P, Macdonald G, Lange A, et al. The role of Doppler left ventricular filling indexes and Doppler tissue echocardiography in the assessment of cardiac involvement in hereditary hemochromatosis. J Am Soc Echocardiogr. 2002;15:884–890
  114. Shizukuda Y, Bolan CD, Tripodi DJ, et al. Left ventricular systolic function during stress echocardiography exercise in subjects with asymptomatic hereditary hemochromatosis. Am J Cardiol. 2006;98:694–698
  115. Cecchetti G, Binda A, Piperno A, et al. Cardiac alterations in 36 consecutive patients with idiopathic haemochromatosis: polygraphic and echocardiographic evaluation. Eur Heart J. 1991;12:224–230
  116. Waxman S, Eustace S, Hartnell GG. Myocardial involvement in primary hemochromatosis demonstrated by magnetic resonance imaging. Am Heart J. 1994;128:1047–1049
  117. Ptaszek LM, Price ET, Hu MY, et al. Early diagnosis of hemochromatosis-related cardiomyopathy with magnetic resonance imaging. J Cardiovasc Magn Reson. 2005;7:689–692
  118. Roest M, van der Schouw YT, de Valk B, et al. Heterozygosity for a hereditary hemochromatosis gene is associated with cardiovascular death in women. Circulation. 1999;100:1268–1273
  119. Strobel JS, Fuisz AR, Epstein AE, et al. Syncope and inducible ventricular fibrillation in a woman with hemochromatosis. J Interv Card Electrophysiol. 1999;3:225–229
  120. Luis Morinigo J, Martin Luengo C, Ledesma C, et al. Ventricular tachycardia and cardiac hemochromatosis. Rev Esp Cardiol. 2001;54:1328–1331
  121. Lemery R, Brugada P, Havenith M, et al. Sudden death in hemochromatosis after closed-chest catheter ablation of the atrioventricular junction. Am J Cardiol. 1988;61:941–943
  122. Yalcinkaya S, Kumbasar SD, Semiz E, et al. Sustained ventricular tachycardia in cardiac hemochromatosis treated with amiodarone. J Electrocardiol. 1997;30:147–149
  123. Durand E, Grinda JM, Bruneval P. Cardiogenic shock in a young woman revealing juvenile haemochromatosis. Heart. 2003;89:870
  124. Dabestani A, Child JS, Henze E, et al. Primary hemochromatosis: anatomic and physiologic characteristics of the cardiac ventricles and their response to phlebotomy. Am J Cardiol. 1984;54:153–159
  125. Rivers J, Garrahy P, Robinson W, et al. Reversible cardiac dysfunction in hemochromatosis. Am Heart J. 1987;113:216–217

PII: S0033-0620(07)00102-8

doi: 10.1016/j.pcad.2007.10.003

Progress in Cardiovascular Diseases
Volume 51, Issue 1 , Pages 58-73 , July 2008

Article Tools

* Image Usage & Resolution